Market Place
Sourcing Support
OKYO Pharma to Present at Tear Film & Ocular Surface Society
30 Oct 2024 //
GLOBENEWSWIRE
OKYO Pharma Doses First Patient in Neuropathic Pain Trial
23 Oct 2024 //
GLOBENEWSWIRE
Okyo Pharma Starts Phase 2 Trial For Neuropathic Corneal Pain
16 Oct 2024 //
GLOBENEWSWIRE
OKYO Pharma Announces Chairman Acquires Shares
10 Sep 2024 //
GLOBENEWSWIRE
OKYO Pharma Announces Chairman Acquires Shares
05 Sep 2024 //
GLOBENEWSWIRE
OKYO Pharma Granted US Patent For OK-101 In Dry Eye Disease Treatment
27 Aug 2024 //
GLOBENEWSWIRE
OKYO Pharma Announces Chairman Acquires Shares
23 Aug 2024 //
GLOBENEWSWIRE
OKYO Pharma CEO Interview to Air on Bloomberg TV
23 Aug 2024 //
GLOBENEWSWIRE
OKYO Pharma Announces Chairman Acquires Shares
21 Aug 2024 //
GLOBENEWSWIRE
OKYO Pharma Joins H.C. Wainwright Ophthalmology Virtual Conference
15 Aug 2024 //
GLOBENEWSWIRE
OKYO Pharma Granted European Patent For OK-101 Chemerin Analogs
06 Aug 2024 //
GLOBENEWSWIRE
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
11 Jul 2024 //
GLOBENEWSWIRE
OKYO Pharma Announces OK-101 Phase 2 Clinical Trial Data For Dry Eye Disease
10 Jul 2024 //
PRESS RELEASE
OKYO Pharma Announces Positive OK-101 Phase 2 Dry Eye Disease Data
10 Jul 2024 //
GLOBENEWSWIRE
OKYO Pharma Announces Participation in May 2024 Investor Conferences
08 May 2024 //
GLOBENEWSWIRE
OKYO Pharma to Present OK-101 Ph2 Dry Eye Data at ARVO
30 Apr 2024 //
GLOBENEWSWIRE
OKYO to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
08 Apr 2024 //
GLOBENEWSWIRE
OKYO Pharma Announces Presentation of OK-101 Ph 2 Data for Dry Eye Disease
02 Apr 2024 //
GLOBENEWSWIRE
OKYO to Discuss New and Comprehensive Data from Ph 2 Dry Eye Disease Trial
21 Mar 2024 //
GLOBENEWSWIRE
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
09 Feb 2024 //
GLOBENEWSWIRE
OKYO Pharma Announces Ophthalmologists with Expertise in the Medical Treatment
31 Jan 2024 //
GLOBENEWSWIRE
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance
08 Jan 2024 //
GLOBENEWSWIRE
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco
05 Jan 2024 //
GLOBENEWSWIRE
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial
04 Dec 2023 //
GLOBENEWSWIRE
OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction
31 Oct 2023 //
GLOBENEWSWIRE
OKYO Pharma Announces Filing of an IND Application for OK-101
09 Oct 2023 //
GLOBENEWSWIRE
OKYO Pharma Announces Data Profile for OK-101 Phase 2 Clinical Trial
05 Oct 2023 //
GLOBENEWSWIRE
OKYO Announces Closing of $4.0 Million Registered Direct Offering of Shares
15 Sep 2023 //
GLOBENEWSWIRE
OKYO Pharma Limited Announces Withdrawal of Public Offering
14 Sep 2023 //
GLOBENEWSWIRE
OKYO Announces Pricing of $4.0 Million Registered Direct Offering of Shares
14 Sep 2023 //
GLOBENEWSWIRE
OKYO Pharma Completes Enrollment in Phase 2 Clinical Trial of OK-101
08 Sep 2023 //
GLOBENEWSWIRE
OKYO Pharma Achieves 90% Enrollment in 240-Patient Ph2 Trial of OK-101
30 Aug 2023 //
GLOBENEWSWIRE
OKYO Pharma Regains Compliance with Nasdaq Listing Minimum Market Value Rule
29 Aug 2023 //
GLOBENEWSWIRE
OKYO Pharma Reports Annual Results for the Twelve Months Ended March 31, 2023
15 Aug 2023 //
GLOBENEWSWIRE
Okyo withdraws offer to sell shares after just 3 days
31 Jul 2023 //
FIERCE BIOTECH
OKYO Pharma Plans to Initiate PII of OK-101 in Neuropathic Corneal Pain
28 Jul 2023 //
GLOBENEWSWIRE
OKYO Pharma Limited Receives Nasdaq Deficiency Notice
28 Jul 2023 //
GLOBENEWSWIRE
OKYO Pharma Announces Proposed Public Offering of Ordinary Shares
28 Jul 2023 //
GLOBENEWSWIRE
OKYO Announces Appointment of William A. Clementi as Chief Operating Officer
27 Jul 2023 //
GLOBENEWSWIRE
OKYO Pharma Announces Phase 2 Clinical Trial of Topical Ocular OK-101
06 Jun 2023 //
GLOBENEWSWIRE
OKYO Pharma Participating on Webull Corporate Communications Service Platform
11 May 2023 //
GLOBENEWSWIRE
OKYO Pharma Announces Presentations at (ASCRS 2023) in San Diego, CA
03 May 2023 //
GLOBENEWSWIRE
OKYO Pharma Announces First-Patient First-Visit for Phase 2 Trial OK-101
02 May 2023 //
BIOSPACE
OKYO Pharma Announces Activation of First Clinical Trial SiteU.S. for the Ph2
25 Apr 2023 //
GLOBENEWSWIRE
OKYO Pharma Management Takes Company Stock In Private Placement
18 Apr 2023 //
ACCESSWIRE
Notice of General Meeting and Publication of Circular
05 Apr 2023 //
GLOBENEWSWIRE
OKYO Pharma Today Announces Director Acquires Shares
30 Mar 2023 //
GLOBENEWSWIRE
OKYO Pharma Today Announces Director Acquires Shares
29 Mar 2023 //
GLOBENEWSWIRE
OKYO Pharma Announces PDMR Dealing
24 Mar 2023 //
GLOBENEWSWIRE
Closing of Global Private Placement
16 Mar 2023 //
PRESS RELEASE
OKYO Announces PII Trial of OK-101 Drug is listed on ClinicalTrials.gov Website
16 Mar 2023 //
GLOBENEWSWIRE
OKYO Pharma Limited announces U.S.$5.74 million Global Private Placement
14 Mar 2023 //
GLOBENEWSWIRE
OKYO Pharma Limited Prices $5.3 Million Offering of ADSs
13 Mar 2023 //
GLOBENEWSWIRE
OKYO Announces Clearance of GMP Packaged OK-101 Drug to be Used in PII Trial
28 Feb 2023 //
GLOBENEWSWIRE
OKYO Announces Appointment of Dr. Jay S. Pepose to Scientific Advisory Board
23 Feb 2023 //
GLOBENEWSWIRE
OKYO Pharma to Present at the Second Annual GPCRs-Targeted Drug Discovery Summit
21 Feb 2023 //
GLOBENEWSWIRE
OKYO to Participate at Biotech Showcase
21 Dec 2022 //
GLOBENEWSWIRE
OKYO Pharma Announces U.S. FDA Clearance of IND Application for OK-101
21 Dec 2022 //
GLOBENEWSWIRE
OKYO Pharma Limited - OKYO publicly files a registrationSEC
06 Dec 2022 //
GLOBENEWSWIRE
OKYO Pharma Limited - Change of Auditor
01 Dec 2022 //
GLOBENEWSWIRE
